Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003;2:14. doi:10.1186/1476-4598-2-14. PMID:12605717.
   PubMedGoogle Scholar
• Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, Talamonti MS. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007;110:738–44. doi:10.1002/cncr.22852. PMID:17580363.
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, Ward E. The convergence of lung cancer rates between blacks and whites under the age of 40, United States. Cancer Epidemiol Biomarkers Prev. 2009;18:3349–52. doi:10.1158/1055-9965.EPI-09-0740. PMID:19959681.
   PubMed Web of Science ®Google Scholar
• Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009;6:412–22. doi:10.1038/nrgastro.2009.89. PMID:19506583.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Therapeutics. 2007;6:1186–97. doi:10.1158/1535-7163.MCT-06-0686..
   PubMed Web of Science ®Google Scholar
• Herreros-Villanueva M, Hijona E, Banales JM, Cosme A, Bujanda L. Alcohol consumption on pancreatic diseases. World J Gastroenterol. 2013;19:638–47. doi:10.3748/wjg.v19.i5.638. PMID:23429423.
   PubMed Web of Science ®Google Scholar
• Fiorino S, Cuppini A, Castellani G, Bacchi-Reggiani ML, Jovine E. HBV- and HCV-related infections and risk of pancreatic cancer. JOP. 2013;14:603–9. PMID:24216545.
   PubMedGoogle Scholar
• Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501. doi:10.1038/nature14169. PMID:25719666.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol. 2017;39:1010428317692231. doi:10.1177/1010428317692231. PMID:28618958.
   PubMedGoogle Scholar
• Creaney J, Robinson BWS. Malignant Mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest. 2017;152:143–9. doi:10.1016/j.chest.2016.12.004. PMID:28007619.
   PubMed Web of Science ®Google Scholar
• Peng X, Guan JL. Focal adhesion kinase: from in vitro studies to functional analyses in vivo. Curr Protein Pept Sci. 2011;12:52–67. doi:10.2174/138920311795659452. PMID:21190526.
   PubMed Web of Science ®Google Scholar
• Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995;15:954–63. doi:10.1128/MCB.15.2.954. PMID:7529876.
   PubMed Web of Science ®Google Scholar
• Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003;116:1409–16. doi:10.1242/jcs.00373. PMID:12640026.
   PubMed Web of Science ®Google Scholar
• Gates RE, King LE, Jr., Hanks SK, Nanney LB. Potential role for focal adhesion kinase in migrating and proliferating keratinocytes near epidermal wounds and in culture. Cell Growth Differ. 1994;5:891–9. PMID:7986754.
   PubMedGoogle Scholar
• Moissoglu K, Gelman IH. v-Src rescues actin-based cytoskeletal architecture and cell motility and induces enhanced anchorage independence during oncogenic transformation of focal adhesion kinase-null fibroblasts. J Biol Chem. 2003;278:47946–59. doi:10.1074/jbc.M302720200. PMID:14500722.
   PubMed Web of Science ®Google Scholar
• Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, Kozuka Y, Ogawa T, Shiraishi T, Imanaka-Yoshida K. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol. 2011;178:754–63. doi:10.1016/j.ajpath.2010.10.015. PMID:21281808.
   PubMed Web of Science ®Google Scholar
• Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377:539–44. doi:10.1038/377539a0. PMID:7566154.
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM, Zheng M, Zhang L, Li JL, Cance WG. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer. 2009;9:280. doi:10.1186/1471-2407-9-280. PMID:19671193.
   PubMed Web of Science ®Google Scholar
• Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochemistry. 2015;63:114–28. doi:10.1369/0022155414561498..
   PubMed Web of Science ®Google Scholar
• Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007;282:14845–52. doi:10.1074/jbc.M606695200. PMID:17395594.
   PubMed Web of Science ®Google Scholar
• Mills RD, Mita M, Nakagawa J, Shoji M, Sutherland C, Walsh MP. A role for the tyrosine kinase Pyk2 in depolarization-induced contraction of vascular smooth muscle. J Biol Chem. 2015;290:8677–92. doi:10.1074/jbc.M114.633107. PMID:25713079.
   PubMed Web of Science ®Google Scholar
• Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, Pandya SS, Bedard PL, Pierce KJ, Houk B, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33:1100–7. doi:10.1007/s10637-015-0282-y. PMID:26334219.
   PubMed Web of Science ®Google Scholar
• Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, et al. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PloS One. 2014;9:e105919. doi:10.1371/journal.pone.0105919. PMID:25221930.
   PubMed Web of Science ®Google Scholar
• Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R. PI3 Kinase pathway and MET inhibition is efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016;6:32992. doi:10.1038/srep32992. PMID:27623107.
   PubMed Web of Science ®Google Scholar
• Wegener J, Keese CR, Giaever I. Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. Exp Cell Res. 2000;259:158–66. doi:10.1006/excr.2000.4919. PMID:10942588.
   PubMed Web of Science ®Google Scholar
• Boj SF, Hwang CI, Baker LA, Engle DD, Tuveson DA, Clevers H. Model organoids provide new research opportunities for ductal pancreatic cancer. Mol Cell Oncol. 2016;3:e1014757. doi:10.1080/23723556.2015.1014757. PMID:27308531.
   PubMed Web of Science ®Google Scholar
• Szulcek R, Bogaard HJ, van Nieuw Amerongen GP. Electric cell-substrate impedance sensing for the quantification of endothelial proliferation, barrier function, and motility. J Vis Exp. 2014. doi:10.3791/51300. PMID:24747269.
   PubMed Web of Science ®Google Scholar
• Wegener J, Janshoff A, Galla HJ. Cell adhesion monitoring using a quartz crystal microbalance: comparative analysis of different mammalian cell lines. Eur Biophys J. 1999;28:26–37. doi:10.1007/s002490050180. PMID:9933921.
   PubMed Web of Science ®Google Scholar
• Kurenova E, Xu LH, Yang X, Baldwin AS, Jr., Craven RJ, Hanks SK, Liu ZG, Cance WG. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol. 2004;24:4361–71. doi:10.1128/MCB.24.10.4361-4371.2004. PMID:15121855.
   PubMed Web of Science ®Google Scholar
• Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal. 2008;1:pe22. doi:10.1126/stke.120pe22. PMID:18493017.
   PubMed Web of Science ®Google Scholar
• Corsi JM, Rouer E, Girault JA, Enslen H. Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics. 2006;7:198. doi:10.1186/1471-2164-7-198. PMID:16889663.
   PubMed Web of Science ®Google Scholar
• Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K, Koizumi M, Kida A, Kawaguchi Y, Fujimoto K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006;30:219–26. doi:10.1007/s00268-005-0165-z. PMID:16425085.
   PubMed Web of Science ®Google Scholar
• Chatzizacharias NA, Giaginis C, Zizi-Serbetzoglou D, Kouraklis GP, Karatzas G, Theocharis SE. Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas. 2010;39:930–6. doi:10.1097/MPA.0b013e3181d7abcc. PMID:20431421.
   PubMed Web of Science ®Google Scholar
• Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T. Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol Cancer. 2005;4:37. doi:10.1186/1476-4598-4-37. PMID:16209712.
   PubMed Web of Science ®Google Scholar
• Li S, Hua ZC. FAK expression regulation and therapeutic potential. Adv Cancer Res. 2008;101:45–61. doi:10.1016/S0065-230X(08)00403-X. PMID:19055942.
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68. doi:10.1126/scitranslmed.3008639. PMID:24848258.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22:851–60. doi:10.1038/nm.4123. PMID:27376576.
   PubMed Web of Science ®Google Scholar
• Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, et al. Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015;163:160–73. doi:10.1016/j.cell.2015.09.001. PMID:26406376.
   PubMed Web of Science ®Google Scholar
• Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem. 2008;51:7405–16. doi:10.1021/jm800483v. PMID:18989950.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T, Haisa M, et al. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res. 2008;14:4631–9. doi:10.1158/1078-0432.CCR-07-4755. PMID:18628478.
   PubMed Web of Science ®Google Scholar
• Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009;28:35–49. doi:10.1007/s10555-008-9165-4. PMID:19169797.
   PubMed Web of Science ®Google Scholar
• Zhang J, He DH, Zajac-Kaye M, Hochwald SN. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13:3143–9. doi:10.4161/15384101.2014.949550. PMID:25486573.
   PubMed Web of Science ®Google Scholar
• Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS. Development of small-molecule cyclin D1-ablative agents. J Med Chem. 2006;49:4684–9. doi:10.1021/jm060057h. PMID:16854074.
   PubMed Web of Science ®Google Scholar
• Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24. doi:10.1186/1476-4598-6-24. PMID:17407548.
   PubMed Web of Science ®Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598–610. doi:10.1038/nrc3792. PMID:25098269.
   PubMed Web of Science ®Google Scholar
• Cabrita MA, Jones LM, Quizi JL, Sabourin LA, McKay BC, Addison CL. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol. 2011;5:517–26. doi:10.1016/j.molonc.2011.10.004. PMID:22075057.
   PubMed Web of Science ®Google Scholar